Elenae Therapeutics, Inc.
Elenae Therapeutics is a platform RNA medicine company that aims to treat aging-related diseases with AI-designed antisense oligonucleotides. It uses locked nucleic acid (LNA) ASO mixmers with a phosphorothioate backbone to target microRNAs implicated in heart failure, dry AMD, sarcopenia, and rare muscular dystrophies. The technology enables tissue penetration into heart, skeletal muscle, retina, and lung, with once-weekly to monthly subcutaneous delivery. Elenae’s approach combines AI design with established ASO chemistry to deliver targeted gene silencing with a strong safety profile demonstrated in preclinical models. The company targets a large and growing market of aging-related and rare diseases, leveraging its incubator-based operations near UC Berkeley to scale.
Elenae Therapeutics, Inc.
Elenae Therapeutics is a platform RNA medicine company that aims to treat aging-related diseases with AI-designed antisense oligonucleotides. It uses locked nucleic acid (LNA) ASO mixmers with a phosphorothioate backbone to target microRNAs implicated in heart failure, dry AMD, sarcopenia, and rare muscular dystrophies. The technology enables tissue penetration into heart, skeletal muscle, retina, and lung, with once-weekly to monthly subcutaneous delivery. Elenae’s approach combines AI design with established ASO chemistry to deliver targeted gene silencing with a strong safety profile demonstrated in preclinical models. The company targets a large and growing market of aging-related and rare diseases, leveraging its incubator-based operations near UC Berkeley to scale.